178 related articles for article (PubMed ID: 21502814)
1. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer.
Jiang Z; Jones R; Liu JC; Deng T; Robinson T; Chung PE; Wang S; Herschkowitz JI; Egan SE; Perou CM; Zacksenhaus E
Cell Cycle; 2011 May; 10(10):1563-70. PubMed ID: 21502814
[TBL] [Abstract][Full Text] [Related]
2. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.
Jiang Z; Deng T; Jones R; Li H; Herschkowitz JI; Liu JC; Weigman VJ; Tsao MS; Lane TF; Perou CM; Zacksenhaus E
J Clin Invest; 2010 Sep; 120(9):3296-309. PubMed ID: 20679727
[TBL] [Abstract][Full Text] [Related]
3. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
4. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
5. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
[TBL] [Abstract][Full Text] [Related]
6. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.
Robinson TJ; Liu JC; Vizeacoumar F; Sun T; Maclean N; Egan SE; Schimmer AD; Datti A; Zacksenhaus E
PLoS One; 2013; 8(11):e78641. PubMed ID: 24265703
[TBL] [Abstract][Full Text] [Related]
7. Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution.
Kumar P; Mukherjee M; Johnson JP; Patel M; Huey B; Albertson DG; Simin K
PLoS Genet; 2012; 8(11):e1003027. PubMed ID: 23173005
[TBL] [Abstract][Full Text] [Related]
8. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
9. Activation of epithelial-mesenchymal transition process during breast cancer progression - the impact of molecular subtype and stromal composition.
Markiewicz A; Topa J; Popęda M; Szade J; Skokowski J; Wełnicka-Jaśkiewicz M; Żaczek A
Acta Biochim Pol; 2021 Aug; 68(3):385-392. PubMed ID: 34432400
[TBL] [Abstract][Full Text] [Related]
10. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
11. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
[TBL] [Abstract][Full Text] [Related]
12. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
[TBL] [Abstract][Full Text] [Related]
13. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.
Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y
Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770
[TBL] [Abstract][Full Text] [Related]
14. Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
Hacking SM; Yakirevich E; Wang Y
J Pathol Clin Res; 2023 Jul; 9(4):313-321. PubMed ID: 37082801
[TBL] [Abstract][Full Text] [Related]
15. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
16. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.
Herschkowitz JI; Zhao W; Zhang M; Usary J; Murrow G; Edwards D; Knezevic J; Greene SB; Darr D; Troester MA; Hilsenbeck SG; Medina D; Perou CM; Rosen JM
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2778-83. PubMed ID: 21633010
[TBL] [Abstract][Full Text] [Related]
17. Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer.
Chung WC; Zhang S; Challagundla L; Zhou Y; Xu K
Neoplasia; 2017 Nov; 19(11):885-895. PubMed ID: 28938159
[TBL] [Abstract][Full Text] [Related]
18. [Triple-negative breast cancer: analysis of patients diagnosed and/or treated at the Masaryk Memorial Cancer Institute between 2004 and 2009].
Svoboda M; Navrátil J; Fabian P; Palácová M; Gombošová J; Slámová L; Princ D; Syptáková B; Kudláček A; Bílek O; Pospíšil P; Kazda T; Grell P; Poprach A; Selingerová I; Nenutil R; Juráček J; Héžová R; Slabý O; Vyzula R
Klin Onkol; 2012; 25(3):188-98. PubMed ID: 22724568
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer--current status and future directions.
Gluz O; Liedtke C; Gottschalk N; Pusztai L; Nitz U; Harbeck N
Ann Oncol; 2009 Dec; 20(12):1913-27. PubMed ID: 19901010
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]